Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 1 5Phase NA 1Phase 3 1Phase 2 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 10Lymphoma 8Lymphoma, Large B-Cell, Diffuse 7Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 5Lymphoma, Mantle-Cell 5Neoplasms 3Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Hairy Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Burkitt Lymphoma 1Anemia 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × obinutuzumab × Clear all
NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT05896163 2026-05-06

MAPtivate-6

Pfizer

Phase 1/2 Terminated
40 enrolled
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05533775 2026-05-04

iMATRIX GLO

Hoffmann-La Roche

Phase 1/2 Recruiting
65 enrolled

Recurrence

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Celgene

Phase 1/2 Active not recruiting
438 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT02600897 2023-12-26

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 1/2 Completed
114 enrolled 34 charts
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡